{"product_id":"dischem-swot-analysis","title":"Dis-Chem SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDis-Chem’s SWOT highlights robust retail reach and pharma expertise alongside margin pressures and competitive risks; our full SWOT unpacks market dynamics, regulatory exposure, and expansion levers with actionable recommendations—purchase the complete analysis for a professionally formatted Word report and editable Excel tools to support investment, strategy, or pitch-ready work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Dispensary Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDis-Chem leads South Africa’s dispensary market, operating over 170 stores with dispensaries and capturing an estimated 30–35% share of the chronic medication market as of 2024; this scale drove R3.4 billion in pharmacy sales in FY2024, reinforcing recurring revenue from repeat prescriptions. The chain’s professional pharmacist advice and broad formulary sustain high customer trust and steady foot traffic across its network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Loyalty Program and Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Dis-Chem Benefit Program, with over 6 million active members as of Dec 2025, yields high-resolution purchase data that lets Dis-Chem run targeted campaigns and personalize offers; loyalty-driven customers spend ~25% more per basket and exhibit 15–20% higher retention, so using analytics for cross-sell lifted pharmacy and retail attach rates by ~8 percentage points in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Supply Chain via CJ Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOwnership of CJ Distribution gives Dis-Chem a vertically integrated supply chain that cut logistics cost by about 7% and improved wholesale margins to roughly 12% in FY2024, boosting group gross margin by 0.8 percentage points. This internal control lets Dis-Chem hold optimized inventory—DIO fell to 38 days in 2024—reducing stockouts during 2023–24 supply shocks. It also ensured retail fill rates above 95% through 2024, protecting sales and customer loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Product Mix and One-Stop Shop Appeal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDis-Chem positions itself as a full health and beauty destination, not just a pharmacy, driving higher basket sizes; in FY2024 Dis-Chem reported R18.3bn revenue, with non-prescription categories (beauty, vitamins, baby care) contributing roughly 42% of sales.\u003c\/p\u003e\n\u003cp\u003eThis wide assortment—vitamins, sports nutrition, beauty, baby care—draws diverse age groups and encourages incidental buys, helping Dis-Chem hold market share against niche retailers; average transaction value rose ~6% in 2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003eR18.3bn revenue FY2024\u003c\/li\u003e\n\u003cli\u003e~42% sales from non-prescription categories\u003c\/li\u003e\n\u003cli\u003eAverage transaction value +6% in 2024\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Healthcare Service Integration through Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDis-Chem’s in-store clinics offer primary care, vaccinations, and screenings, boosting average monthly footfall by up to 12% at clinic sites and increasing basket size; clinics contributed an estimated ZAR 240 million in ancillary sales in 2024.\u003c\/p\u003e\n\u003cp\u003eThese services deepen local healthcare ties—over 300 clinics nationwide as of Dec 2024—raising repeat customer rates and strengthening brand equity through accessible consultations and community trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~300 clinics (Dec 2024)\u003c\/li\u003e\n\u003cli\u003e+12% footfall at clinic locations\u003c\/li\u003e\n\u003cli\u003eZAR 240m ancillary sales (2024)\u003c\/li\u003e\n\u003cli\u003eHigher repeat-customer and brand trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket leader: R18.3bn group, 170+ dispensaries, 6M+ loyalty members boosting sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket leader with 170+ dispensary stores, ~30–35% chronic med share (2024), R3.4bn pharmacy sales FY2024; R18.3bn group revenue FY2024 with ~42% non-prescription sales. 6m+ loyalty members (Dec 2025) drive +25% basket spend; CJ Distribution cuts logistics ~7%, DIO 38 days (2024); ~300 clinics (Dec 2024) adding ZAR 240m ancillary sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStores w\/dispensary\u003c\/td\u003e\n\u003ctd\u003e170+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic market share (2024)\u003c\/td\u003e\n\u003ctd\u003e30–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue FY2024\u003c\/td\u003e\n\u003ctd\u003eR18.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy sales FY2024\u003c\/td\u003e\n\u003ctd\u003eR3.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoyalty members\u003c\/td\u003e\n\u003ctd\u003e6m+ (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDIO (2024)\u003c\/td\u003e\n\u003ctd\u003e38 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics (Dec 2024)\u003c\/td\u003e\n\u003ctd\u003e~300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAncillary sales (2024)\u003c\/td\u003e\n\u003ctd\u003eZAR 240m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Dis-Chem, highlighting internal strengths and weaknesses alongside external opportunities and threats to assess its competitive position and strategic growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Dis-Chem SWOT matrix for rapid strategic alignment, ideal for executives needing a quick snapshot of competitive positioning and growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in South Africa\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 90% of Dis-Chem Group’s FY2024 revenue came from South Africa, leaving it exposed to local GDP shocks; a 1% drop in SA GDP (IMF 2024) can meaningfully dent sales given limited international sales.\u003c\/p\u003e\n\u003cp\u003eThis concentration caps growth versus peers like Boots or Walgreens with multi-country footprints and reduces upside from faster-growing African markets.\u003c\/p\u003e\n\u003cp\u003ePolitical or social unrest—e.g., SA’s 2021 riots that cut retail footfall by an estimated 6–8% in affected areas—would hit Dis-Chem’s EBITDA margin directly, with little geographic hedge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Regulated Pricing Structures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSouth Africa caps medicine margins via the Single Exit Price (SEP), squeezing gross margins on Dis-Chem’s pharmaceutical segment; in FY2024 pharma gross margin was ~15% vs total group ~27%, showing constrained profitability. \u003c\/p\u003e\n\u003cp\u003eSEP limits price responses to rising input and wage costs, so Dis-Chem’s pharmacy margins fell 120 basis points in 2024, forcing cost control and margin pressure. \u003c\/p\u003e\n\u003cp\u003eAs a result, Dis-Chem depends on non-regulated front-shop sales—cosmetics, health supplements, OTC—which made ~62% of retail gross profit in FY2024 to sustain overall margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Operational and Debt Servicing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cprising utility and logistics costs eroded dis-chem operating margin to about in fy2024 down from the prior year squeezing cash flow. retailer capital spending for store rollouts acquisitions pushed net debt roughly zar billion by fy2025. with south african prime rates near early interest expense surged limiting free reinvestment. this heightens refinancing growth risks.\u003e\n\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Inventory Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging over 60,000 SKUs across 800+ Dis-Chem stores creates logistics strain and admin overhead, raising error rates and reordering complexity.\u003c\/p\u003e\n\u003cp\u003eHigh inventory tied up ~R3.2bn in working capital at FY2024, increasing holding costs and obsolescence risk in fast-moving beauty and nutrition lines.\u003c\/p\u003e\n\u003cp\u003eOptimizing local product mix needs advanced store-level replenishment systems; estimated IT and upgrade spend exceeded R120m in 2024 and rises with scale.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60,000+ SKUs, 800+ stores\u003c\/li\u003e\n\u003cli\u003e~R3.2bn working capital in inventory (FY2024)\u003c\/li\u003e\n\u003cli\u003eR120m+ IT\/upgrades (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Local Labor Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs one of South Africa’s largest retail employers with ~11,000 staff (2024), Dis-Chem faces risk from union-driven wage demands that can raise operating costs and compress margins.\u003c\/p\u003e\n\u003cp\u003ePeriodic strikes—such as pharmacy sector actions in 2023 that hit footfall—can disrupt supply chains, stores and damage brand trust, lowering short-term sales.\u003c\/p\u003e\n\u003cp\u003eManagement must balance fair wages against cost control; a 1% wage increase could cut FY operating profit by an estimated ~ZAR30–50m based on 2024 margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~11,000 employees (2024)\u003c\/li\u003e\n\u003cli\u003e1% wage rise ≈ ZAR30–50m profit impact\u003c\/li\u003e\n\u003cli\u003e2023 sector strikes reduced footfall\/sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDis‑Chem risk: SA concentration, razor‑thin pharma margins and rising debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy SA concentration (~90% FY2024 revenue) exposes Dis-Chem to local GDP, political unrest and SEP price caps that compressed pharma margins to ~15% vs group ~27%, forcing reliance on non-regulated front-shop sales (~62% retail gross profit). High costs raised net debt to ~ZAR5.1bn (FY2025) and cut operating margin to ~4.2%; inventory tied ~R3.2bn working capital (FY2024), ~11,000 staff add wage\/strike risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration (SA)\u003c\/td\u003e\n\u003ctd\u003e~90% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma gross margin\u003c\/td\u003e\n\u003ctd\u003e~15% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup gross margin\u003c\/td\u003e\n\u003ctd\u003e~27% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail front-shop profit\u003c\/td\u003e\n\u003ctd\u003e~62% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e~4.2% FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e~ZAR5.1bn FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory WC\u003c\/td\u003e\n\u003ctd\u003e~R3.2bn FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~11,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eDis-Chem SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Dis-Chem SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752574595449,"sku":"dischem-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dischem-swot-analysis.png?v=1772242545","url":"https:\/\/growthsharematrix.com\/products\/dischem-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}